Kitov Pharmaceuticals announces FDA approval of Consensi.
Kitov Pharma announced that the U.S. Food and Drug Administration has approved Consensi oral tablets for marketing. Consensi is a patent-protected combination of celecoxib, a non-steroidal anti-inflammatory drug, and amlodipine besylate, an antihypertensive calcium channel blocker. Consensi was approved for once daily use in three dosage forms, corresponding to the current approved dosages of amlodipine for hypertension and a 200 mg dose of celecoxib for the treatment of osteoarthritis pain. "We recently expanded our commercialization network for Consensi by securing a second licensing agreement in Asia with a major Chinese pharmaceutical company. The FDA approval of Consensi puts us in a stronger position towards securing commercial partnerships for the U.S. and other key territories...Now that Consensi has been approved for marketing, our clinical and regulatory teams will focus on leveraging their drug development expertise to advance NT219, an exciting investigational new drug candidate currently in development for various oncology indications," executives of Kitov stated.
|Printer friendly Cite/link Email Feedback|
|Date:||May 31, 2018|
|Previous Article:||Developments at Allergan, Biogen indirectly positive for Alder, says RBC Capital.|
|Next Article:||Madrigal price target raised to $300 from $175 at Evercore ISI.|